Frequency:every 4 weeks (i.e.28 days)

2 trials

Sponsors

Celerity Pharmaceuticals LLC

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: C569- Malignant neoplasm of unspecifiedovary

Unknown Phase

A Study of Doxorubicin Hydrochloride Liposome Injection in Patients with Ovarian Cancer.

Active, not recruitingCTRI/2018/08/015266

Celerity Pharmaceuticals LLCHealth Condition 1: C569- Malignant neoplasm of unspecifiedovary

Target: 76Updated: 2021-11-24

A Study of Doxorubicin Hydrochloride Injection in Patients with Breast Cancer

Active, not recruitingCTRI/2018/08/015325

Celerity Pharmaceuticals LLCHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site

Target: 76Updated: 2021-11-24